Literature DB >> 22119905

[Heart rate and rate control : Prognostic value in cardiovascular diseases].

F Custodis1, J-C Reil, U Laufs, M Böhm.   

Abstract

Resting heart rate represents a cardiovascular risk indicator and an important target of therapy in chronic heart failure and potentially in coronary artery disease. Clinical and experimental evidence suggests that sustained elevation of heart rate - independent of the underlying trigger - plays a causal role in the pathogenesis of vascular disease. Results of the SHIFT trial support the importance of heart-rate reduction with ivabradine for improvement of clinical outcomes in heart failure and confirm the role of heart rate as a risk factor for patients with severe left ventricular dysfunction. Results of the BEAUTIFUL trial show that patients with ischemic heart disease and a heart rate above 70 bpm exhibit an adverse prognosis concerning coronary events.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22119905     DOI: 10.1007/s00108-011-2887-3

Source DB:  PubMed          Journal:  Internist (Berl)        ISSN: 0020-9554            Impact factor:   0.743


  37 in total

1.  Meta-analysis: beta-blocker dose, heart rate reduction, and death in patients with heart failure.

Authors:  Finlay A McAlister; Natasha Wiebe; Justin A Ezekowitz; Alexander A Leung; Paul W Armstrong
Journal:  Ann Intern Med       Date:  2009-06-02       Impact factor: 25.391

Review 2.  Vascular pathophysiology in response to increased heart rate.

Authors:  Florian Custodis; Stephan H Schirmer; Magnus Baumhäkel; Gerd Heusch; Michael Böhm; Ulrich Laufs
Journal:  J Am Coll Cardiol       Date:  2010-12-07       Impact factor: 24.094

3.  Long-term prognostic value of resting heart rate in patients with suspected or proven coronary artery disease.

Authors:  Ariel Diaz; Martial G Bourassa; Marie-Claude Guertin; Jean-Claude Tardif
Journal:  Eur Heart J       Date:  2005-03-17       Impact factor: 29.983

4.  Efficacy of ivabradine, a new selective I(f) inhibitor, compared with atenolol in patients with chronic stable angina.

Authors:  Jean-Claude Tardif; Ian Ford; Michal Tendera; Martial G Bourassa; Kim Fox
Journal:  Eur Heart J       Date:  2005-10-07       Impact factor: 29.983

Review 5.  [Pathophysiology of heart failure today].

Authors:  Michael Böhm
Journal:  Herz       Date:  2002-03       Impact factor: 1.443

6.  Heart rate contributes to the vascular effects of chronic mental stress: effects on endothelial function and ischemic brain injury in mice.

Authors:  Florian Custodis; Karen Gertz; Mustafa Balkaya; Vincent Prinz; Ilka Mathar; Christoph Stamm; Golo Kronenberg; Andrey Kazakov; Marc Freichel; Michael Böhm; Matthias Endres; Ulrich Laufs
Journal:  Stroke       Date:  2011-04-28       Impact factor: 7.914

7.  Retarding effect of lowered heart rate on coronary atherosclerosis.

Authors:  P A Beere; S Glagov; C K Zarins
Journal:  Science       Date:  1984-10-12       Impact factor: 47.728

Review 8.  Heart rate lowering by specific and selective I(f) current inhibition with ivabradine: a new therapeutic perspective in cardiovascular disease.

Authors:  Dario DiFrancesco; John A Camm
Journal:  Drugs       Date:  2004       Impact factor: 9.546

9.  Ivabradine for patients with stable coronary artery disease and left-ventricular systolic dysfunction (BEAUTIFUL): a randomised, double-blind, placebo-controlled trial.

Authors:  Kim Fox; Ian Ford; P Gabriel Steg; Michal Tendera; Roberto Ferrari
Journal:  Lancet       Date:  2008-08-29       Impact factor: 79.321

10.  Increased heart rate and reduced heart-rate variability are associated with subclinical inflammation in middle-aged and elderly subjects with no apparent heart disease.

Authors:  Ahmad Sajadieh; Olav Wendelboe Nielsen; Verner Rasmussen; Hans Ole Hein; Sadollah Abedini; Jørgen Fischer Hansen
Journal:  Eur Heart J       Date:  2004-03       Impact factor: 29.983

View more
  2 in total

Review 1.  [Conservative therapy of patients with stable coronary heart disease].

Authors:  F Custodis; U Laufs
Journal:  Herz       Date:  2012-02       Impact factor: 1.443

2.  Effect of ivabradine-induced heart rate reduction on flow-mediated dilation measured with high-sensitivity ultrasound in patients with stable coronary heart disease.

Authors:  Nicoline Jochmann; Franziska Schröter; Fabian Knebel; Robert Hättasch; Christine Gericke; Karl Stangl; Gert Baumann; Verena Stangl
Journal:  Cardiovasc Ultrasound       Date:  2014-01-31       Impact factor: 2.062

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.